Mechthild Krause
Mechthild Krause
Professorin für Translationale Radioonkologie, Universitätsklinikum Dresden/ DKFZ Heidelberg
Verified email at
Cited by
Cited by
Exploring the role of cancer stem cells in radioresistance
M Baumann, M Krause, R Hill
Nature Reviews Cancer 8 (7), 545-554, 2008
Radiation oncology in the era of precision medicine
M Baumann, M Krause, J Overgaard, J Debus, SM Bentzen, J Daartz, ...
Nature Reviews Cancer 16 (4), 234-249, 2016
ESTRO consensus guideline on target volume delineation for elective radiation therapy of early stage breast cancer
BV Offersen, LJ Boersma, C Kirkove, S Hol, MC Aznar, AB Sola, ...
Radiotherapy and oncology 114 (1), 3-10, 2015
Cancer stem cells: Radioresistance, prediction of radiotherapy outcome and specific targets for combined treatments
M Krause, A Dubrovska, A Linge, M Baumann
Advanced drug delivery reviews 109, 63-73, 2017
Human gastric cancer modelling using organoids
T Seidlitz, SR Merker, A Rothe, F Zakrzewski, C von Neubeck, ...
Gut 68 (2), 207-217, 2019
Aldehyde dehydrogenase is regulated by β-catenin/TCF and promotes radioresistance in prostate cancer progenitor cells
M Cojoc, C Peitzsch, I Kurth, F Trautmann, LA Kunz-Schughart, ...
Cancer research 75 (7), 1482-1494, 2015
Targeting the epidermal growth factor receptor in radiotherapy: radiobiological mechanisms, preclinical and clinical results
M Baumann, M Krause
Radiotherapy and oncology 72 (3), 257-266, 2004
β1 Integrin/FAK/cortactin signaling is essential for human head and neck cancer resistance to radiotherapy
I Eke, Y Deuse, S Hehlgans, K Gurtner, M Krause, M Baumann, ...
The Journal of clinical investigation 122 (4), 1529-1540, 2012
CD 8+ tumour‐infiltrating lymphocytes in relation to HPV status and clinical outcome in patients with head and neck cancer after postoperative chemoradiotherapy: A multicentre …
P Balermpas, F Rödel, C Rödel, M Krause, A Linge, F Lohaus, ...
International journal of cancer 138 (1), 171-181, 2016
A comparative study of machine learning methods for time-to-event survival data for radiomics risk modelling
S Leger, A Zwanenburg, K Pilz, F Lohaus, A Linge, K Zöphel, J Kotzerke, ...
Scientific reports 7 (1), 13206, 2017
Three-dimensional cell growth confers radioresistance by chromatin density modification
K Storch, I Eke, K Borgmann, M Krause, C Richter, K Becker, E Schröck, ...
Cancer research 70 (10), 3925-3934, 2010
EGFR-targeted anti-cancer drugs in radiotherapy: preclinical evaluation of mechanisms
M Baumann, M Krause, E Dikomey, K Dittmann, W Dörr, U Kasten-Pisula, ...
Radiotherapy and Oncology 83 (3), 238-248, 2007
ESTRO consensus guideline on target volume delineation for elective radiation therapy of early stage breast cancer, version 1.1
BV Offersen, LJ Boersma, C Kirkove, S Hol, MC Aznar, AB Sola, ...
Radiotherapy and oncology 118 (1), 205-208, 2016
Hypofractionated versus standard fractionated radiotherapy in patients with early breast cancer or ductal carcinoma in situ in a randomized phase III trial: the DBCG HYPO trial
BV Offersen, J Alsner, HM Nielsen, EH Jakobsen, MH Nielsen, M Krause, ...
Journal of Clinical Oncology 38 (31), 3615-3625, 2020
Pre-treatment number of clonogenic cells and their radiosensitivity are major determinants of local tumour control after fractionated irradiation
A Yaromina, M Krause, H Thames, A Rosner, M Krause, F Hessel, ...
Radiotherapy and oncology 83 (3), 304-310, 2007
Final results of the randomized phase III CHARTWEL-trial (ARO 97-1) comparing hyperfractionated-accelerated versus conventionally fractionated radiotherapy in non-small cell …
M Baumann, T Herrmann, R Koch, W Matthiessen, S Appold, B Wahlers, ...
Radiotherapy and Oncology 100 (1), 76-85, 2011
HPV16 DNA status is a strong prognosticator of loco-regional control after postoperative radiochemotherapy of locally advanced oropharyngeal carcinoma: results from a …
F Lohaus, A Linge, I Tinhofer, V Budach, E Gkika, M Stuschke, ...
Radiotherapy and oncology 113 (3), 317-323, 2014
HPV status, cancer stem cell marker expression, hypoxia gene signatures and tumour volume identify good prognosis subgroups in patients with HNSCC after primary …
A Linge, F Lohaus, S Löck, A Nowak, V Gudziol, C Valentini, ...
Radiotherapy and Oncology 121 (3), 364-373, 2016
European Society for Radiotherapy and Oncology Advisory Committee in Radiation Oncology Practice consensus recommendations on patient selection and dose and fractionation for …
I Meattini, C Becherini, L Boersma, O Kaidar-Person, GN Marta, ...
The Lancet Oncology 23 (1), e21-e31, 2022
Residual tumour hypoxia in head-and-neck cancer patients undergoing primary radiochemotherapy, final results of a prospective trial on repeat FMISO-PET imaging
S Löck, R Perrin, A Seidlitz, A Bandurska-Luque, S Zschaeck, K Zöphel, ...
Radiotherapy and Oncology 124 (3), 533-540, 2017
The system can't perform the operation now. Try again later.
Articles 1–20